Caribou Biosciences, Inc. · NASDAQ:CRBU
Caribou Biosciences — Corporate Update (April 2024)
19 slides from Caribou Biosciences's corporate update, Apr 4, 2024
Slide 1: Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus
Caribou Biosciences Expands Clinical Development of CB- 010 with FDA Clearance of IND in Lupus April 4, 2024
Slide 2: Forward-looking statements
2 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Forward-looking statements All statements in this presentation, other than statements of historical facts, are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Thes
Slide 3: Caribou's partners in lupus
3 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. ”Lupus is a complex, chronic, heterogeneous autoimmune disease impacting millions of people worldwide, often causing debilitating outcomes. There is a pressing need for more innovative therapies that address the underly
Slide 4: Today's guests
4 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Today’s guests Professor of medicine Director of glomerular disease center Stanford University Richard Lafayette, MD Professor of medicine Section chief of hematologic malignancies Investigator for the ANTLER Phase 1 tr
Slide 5: Advancing pipeline of clinical-stage allogeneic CAR-T cell therapies
5 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Program Clinical trial Target Indication Preclinical Phase 1 Phase 2 Phase 3 Designations CB-010 ANTLER Dose expansion CD19 r/r B-NHL RMAT, Fast Track, Orphan Drug CB-011 CaMMouflage Dose escalation BCMA r/r MM Fast Tra
Slide 6: Allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout for lupus
6 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Allogeneic anti-CD19 CAR-T cell therapy with a PD-1 knockout for lupus CB-010
Slide 7: Lupus is a chronic, inflammatory autoimmune disease driven by autoantibody-producing B cells
7 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Lupus is a chronic, inflammatory autoimmune disease driven by autoantibody-producing B cells Lupus can cause widespread organ damage, increase cardiovascular risk, and significantly impair patient quality of life 1 Li D
Slide 8: CB-010 is an allogeneic CAR-T cell therapy that targets autoantibody-producing B cells
8 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. CB-010 is an allogeneic CAR-T cell therapy that targets autoantibody-producing B cells 1 To Caribou’s knowledge, CB-010 is the first allogeneic CAR-T in the clinic with checkpoint disruption via PD-1 KO 2 Müller F, et a
Slide 9: Donor-derived CAR-T cell therapy precision engineered with chRDNA genome editing
9 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Donor-derived CAR-T cell therapy precision engineered with chRDNA genome editing technology No lentiviral or retroviral vectors for genome editing Precise insertion of CAR using chRDNA genome-editing technology CB-010 a
Slide 10: CB-010 GALLOP Phase 1 trial design
10 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. CB-010 GALLOP Phase 1 trial design v • Non-responsive to glucocorticoids and have tried and failed at least 2 defined immunosuppressive therapies • Excludes cardiac and CNS involvement • Partial HLA matching and absenc
Slide 11: Partial HLA matching to potentially improve patient outcomes
11 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Partial HLA matching to potentially improve patient outcomes DSA: donor-specific antibodies 1Based on data from the ANTLER Phase 1 trial in r/r B-NHL and to be confirmed in the trials; initial data to be presented at m
Slide 12: Fireside chat
Fireside chat CARIBOU > BIOSCIENCES
Slide 13: Fireside chat with leaders in rheumatology and oncology
13 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Fireside chat with leaders in rheumatology and oncology Professor of medicine Director of glomerular disease center Stanford University Richard Lafayette, MD Professor of medicine Section chief of hematologic malignanc
Slide 14: 2024 accomplishments and upcoming milestones
14 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. 2024 accomplishments and upcoming milestones 1 $372.4M in cash, cash equivalents, and marketable securities as of December 31, 2023. Hematologic malignancies CB-010 in 2L LBCL Present initial ANTLER 2L LBCL dose expans
Slide 15: Q&A
Q&A CARIBOU > BIOSCIENCES
Slide 16: Open to your questions
16 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. Open to your questions Professor of medicine Director of glomerular disease center Stanford University Richard Lafayette, MD Professor of medicine Section chief of hematologic malignancies ANTLER Phase 1 trial investig
Slide 17: Thank you
Thank you https://cariboubio.com info@cariboubio.com
Slide 18: Appendix
Appendix CARIBOU > BIOSCIENCES
Slide 19: With gratitude for patients, caregivers, investigators contributing to CB-010's clinical development
19 CB-010 autoimmune conference call | April 2024 ©2024 Caribou Biosciences, Inc. With gratitude for patients, caregivers, investigators contributing to CB-010’s clinical development ANTLER Phase 1 trial: 29 active sites in US, Australia, and Israel Alabama University of Alabama Birmingham (Mehta) A